Join
Live feed
·
PRReleasevia Quantisnow
Avenue Therapeutics Inc. logo
Fortress Biotech Inc. logo

Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease

ByQuantisnow·Wall Street's wire, on your screen.
ATXI· Avenue Therapeutics Inc.FBIO· Fortress Biotech Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ATXI (Avenue Therapeutics Inc.), FBIO (Fortress Biotech Inc.) and more on Quantisnow.